Scholarlink

Background <p>Frail patients with cancer (Ca) have worse survival. Current methods of assessment of fitness (performance status) for cancer treatment, such as chemotherapy, are time -consuming and often not used by practicing oncologists. The electronic frailty index (SCARF) is derived from a cumulative deficit frailty model and provides a measure of frailty alongside pre-existing conditions. We used this methodology to investigate whether it can predict outcomes of chemotherapy in patients with Ca.</p> Methods <p>The study conducted data analysis of Ca patients treated with chemotherapy in England, years 2015–2018; stage II–III breast Ca, stage III colon Ca and stage IIIB–IV non-small-cell lung Ca. The data was linked with hospital admissions to calculate 30-day chemotherapy mortality, overall survival and SCARF.</p> Results <p>The SCARF was calculated for 78,799 patients. The risk of dying within 30 days of chemotherapy in severely frail patients with colorectal cancer ≥70 y.o. was twice that of the &lt;70 y.o. (OR 2.04 −95% CI 1.58–2.64, mild frailty 1.07–95% CI 0.78–1.45); and 6 times higher in breast cancer (OR 5.73–95% CI 2.66–12.32, mild frailty OR 1.45 95% CI 0.78–2.71).</p> Conclusion <p>The SCARF index predicts poor outcomes from SACT, particularly in breast and colon cancer, and it requires further evaluation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The utility of electronic frailty index in cancer patients undergoing chemotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Agnieszka Michael,
  • Jennie Huynh,
  • Katie Sutton,
  • Man-Chie Chow,
  • Elizabeth Ford,
  • Janine Mansi,
  • Peter Selby,
  • Simon Skene,
  • Jo Armes

摘要

Background

Frail patients with cancer (Ca) have worse survival. Current methods of assessment of fitness (performance status) for cancer treatment, such as chemotherapy, are time -consuming and often not used by practicing oncologists. The electronic frailty index (SCARF) is derived from a cumulative deficit frailty model and provides a measure of frailty alongside pre-existing conditions. We used this methodology to investigate whether it can predict outcomes of chemotherapy in patients with Ca.

Methods

The study conducted data analysis of Ca patients treated with chemotherapy in England, years 2015–2018; stage II–III breast Ca, stage III colon Ca and stage IIIB–IV non-small-cell lung Ca. The data was linked with hospital admissions to calculate 30-day chemotherapy mortality, overall survival and SCARF.

Results

The SCARF was calculated for 78,799 patients. The risk of dying within 30 days of chemotherapy in severely frail patients with colorectal cancer ≥70 y.o. was twice that of the <70 y.o. (OR 2.04 −95% CI 1.58–2.64, mild frailty 1.07–95% CI 0.78–1.45); and 6 times higher in breast cancer (OR 5.73–95% CI 2.66–12.32, mild frailty OR 1.45 95% CI 0.78–2.71).

Conclusion

The SCARF index predicts poor outcomes from SACT, particularly in breast and colon cancer, and it requires further evaluation.